OBJECTIVES: Measles was virtually eliminated in South Africa following control activities in 1996/7. However, from July 2003 to November 2005, 1676 laboratory-confirmed measles cases were reported in South Africa. We investigated the outbreak's cause and the role of HIV. DESIGN: We traced laboratory-confirmed case-patients residing in the Johannesburg metropolitan (JBM) and O. R. Tambo districts. We interviewed laboratory--or epidemiologically confirmed case-patients or their caregivers to determine vaccination status and, in JBM, HIV status. We calculated vaccine effectiveness using the screening method. SETTING: Household survey in JBM and O. R. Tambo districts. Outcome measures. Vaccine effectiveness, case-fatality rate, and hospitalisations. RESULTS: In JBM, 109 case-patients were investigated. Of the 57 case-patients eligible for immunisation, 27 (47.4%) were vaccinated. Fourteen (12.8%) case-patients were HIV infected, 46 (42.2%) were HIV uninfected, and 49 (45.0%) had unknown HIV status. Among children aged 12-59 months, vaccine effectiveness was 85% (95% confidence interval (CI): 63, 94) for all children, 63% for HIV infected, 75% for HIV uninfected, and 96% for children with unknown HIV status. (Confidence intervals were not calculated for sub-groups owing to small sample size.) In O. R. Tambo district, 157 case-patients were investigated. Among the 138 case-patients eligible for immunisation, 41 (29.7%) were vaccinated. Vaccine effectiveness was 89% (95% CI 77, 95). CONCLUSIONS: The outbreak's primary cause was failure to vaccinate enough of the population to prevent endemic measles transmission. Although vaccine effectiveness might have been lower in HIV-infected than in uninfected children, population vaccine effectiveness remained high.
OBJECTIVES: Measles was virtually eliminated in South Africa following control activities in 1996/7. However, from July 2003 to November 2005, 1676 laboratory-confirmed measles cases were reported in South Africa. We investigated the outbreak's cause and the role of HIV. DESIGN: We traced laboratory-confirmed case-patients residing in the Johannesburg metropolitan (JBM) and O. R. Tambo districts. We interviewed laboratory--or epidemiologically confirmed case-patients or their caregivers to determine vaccination status and, in JBM, HIV status. We calculated vaccine effectiveness using the screening method. SETTING: Household survey in JBM and O. R. Tambo districts. Outcome measures. Vaccine effectiveness, case-fatality rate, and hospitalisations. RESULTS: In JBM, 109 case-patients were investigated. Of the 57 case-patients eligible for immunisation, 27 (47.4%) were vaccinated. Fourteen (12.8%) case-patients were HIV infected, 46 (42.2%) were HIV uninfected, and 49 (45.0%) had unknown HIV status. Among children aged 12-59 months, vaccine effectiveness was 85% (95% confidence interval (CI): 63, 94) for all children, 63% for HIV infected, 75% for HIV uninfected, and 96% for children with unknown HIV status. (Confidence intervals were not calculated for sub-groups owing to small sample size.) In O. R. Tambo district, 157 case-patients were investigated. Among the 138 case-patients eligible for immunisation, 41 (29.7%) were vaccinated. Vaccine effectiveness was 89% (95% CI 77, 95). CONCLUSIONS: The outbreak's primary cause was failure to vaccinate enough of the population to prevent endemic measles transmission. Although vaccine effectiveness might have been lower in HIV-infected than in uninfected children, population vaccine effectiveness remained high.
Authors: Robin Nandy; Thomas Handzel; Maman Zaneidou; José Biey; Rene Z Coddy; Robert Perry; Peter Strebel; Lisa Cairns Journal: Clin Infect Dis Date: 2005-12-19 Impact factor: 9.079
Authors: David Coetzee; Katherine Hilderbrand; Andrew Boulle; Beverley Draper; Fareed Abdullah; Eric Goemaere Journal: Bull World Health Organ Date: 2005-07 Impact factor: 9.408
Authors: M Otten; R Kezaala; A Fall; B Masresha; R Martin; L Cairns; R Eggers; R Biellik; M Grabowsky; P Strebel; J-M Okwo-Bele; D Nshimirimana Journal: Lancet Date: 2005 Sep 3-9 Impact factor: 79.321
Authors: C A de Quadros; J M Olivé; B S Hersh; M A Strassburg; D A Henderson; D Brandling-Bennett; G A Alleyne Journal: JAMA Date: 1996-01-17 Impact factor: 56.272
Authors: Inácio Mandomando; Denise Naniche; Marcela F Pasetti; Lilian Cuberos; Sergi Sanz; Xavier Vallès; Betuel Sigauque; Eusébio Macete; Delino Nhalungo; Karen L Kotloff; Myron M Levine; Pedro L Alonso Journal: Am J Trop Med Hyg Date: 2011-07 Impact factor: 2.345
Authors: Adam L Cohen; Thomas Taylor; Monica M Farley; William Schaffner; Lindsey J Lesher; Kenneth A Gershman; Nancy M Bennett; Arthur Reingold; Ann Thomas; Joan Baumbach; Lee H Harrison; Susan Petit; Bernard Beall; Elizabeth Zell; Matthew Moore Journal: PLoS One Date: 2012-08-01 Impact factor: 3.240
Authors: Genevie M Ntshoe; Johanna M McAnerney; Brett N Archer; Sheilagh B Smit; Bernice N Harris; Stefano Tempia; Mirriam Mashele; Beverley Singh; Juno Thomas; Ayanda Cengimbo; Lucille H Blumberg; Adrian Puren; Jocelyn Moyes; Johann van den Heever; Barry D Schoub; Cheryl Cohen Journal: PLoS One Date: 2013-02-20 Impact factor: 3.240
Authors: Rebecca F Grais; Peter Strebel; Peter Mala; John Watson; Robin Nandy; Michelle Gayer Journal: Confl Health Date: 2011-09-26 Impact factor: 2.723
Authors: Cristina V Cardemil; Anna Jonas; Anita Beukes; Raydel Anderson; Paul A Rota; Bettina Bankamp; Howard E Gary; Souleymane Sawadogo; Sadhna V Patel; Sikota Zeko; Clementine Muroua; Esegiel Gaeb; Kathleen Wannemuehler; Sue Gerber; James L Goodson Journal: Int J Infect Dis Date: 2016-05-24 Impact factor: 3.623
Authors: C J E Metcalf; C Cohen; J Lessler; J M McAnerney; G M Ntshoe; A Puren; P Klepac; A Tatem; B T Grenfell; O N Bjørnstad Journal: J R Soc Interface Date: 2013-01-06 Impact factor: 4.118